Fuwai Hospital Team at EuroPCR 2026: Practical Strategies & Clinical Data for PCI Optimization 🏥

July 16, 2026

Fuwai Hospital Team at EuroPCR 2026: Practical Strategies & Clinical Data for PCI Optimization 🏥

At EuroPCR 2026, Dr. Kefei Dou’s team from Fuwai Hospital shared 7 clinical studies on the full-cycle management of PCI. These large-cohort findings provide actionable, evidence-based references for optimizing cath lab workflows and patient care.

Here are the practical clinical takeaways:

📌 Pre-op: Optimizing Workflow via CT-COMPASS The 1-year data supports integrating AI-empowered CT virtual stenting (CT-VS) into routine pre-op assessment. 📈 Data: CT-VS reduced Target Vessel Failure (TVF) to 1.5% (vs. 4.4% in the angio-guided group). 🎯 Impact: Optimized pre-op strategies in ~1/3 of patients, avoiding unnecessary interventions.

💊 Post-op: Long-term Antiplatelet Choice for High-Risk Pts For high-risk PCI patients who are event-free after 12 months of standard DAPT: 📈 Data: Clopidogrel monotherapy (months 12-36) reduced MACCE risk by ~57% compared to Aspirin, with no increase in bleeding. 🎯 Impact: A safe, actionable standard for managing complex PCI with High Bleeding Risk (HBR).

📊 Intra-op: Resource Allocation for Physiology (FFR/QFR) To address "which vessels truly need FFR/QFR," the team developed an XGBoost machine-learning model based on angiographic features. 🎯 Impact: Enables rapid, intra-op screening of "net-benefit" vessels, optimizing cath lab resources.

🔬 Follow-up: Refined Risk Stratification 🔍 Inflammation: CCTA-assessed local coronary inflammation is a stronger independent predictor of MACE than systemic inflammation. 🩸 Lipids in DM: For diabetic PCI patients, the LDL-C/ApoB ratio (reflecting LDL particle size) provides a more accurate assessment of residual risk than LDL-C alone.